Área de prevención cardiovascular y rehabilitación cardiaca
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (36)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial
International Journal of Antimicrobial Agents, Vol. 63, Núm. 6
-
Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study
Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607
2023
-
Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry
Scientific Reports, Vol. 13, Núm. 1
-
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis
Frontiers in Cellular and Infection Microbiology, Vol. 13
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
-
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125
2022
-
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Open Forum Infectious Diseases
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
Life science alliance, Vol. 5, Núm. 4
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
BMC Infectious Diseases, Vol. 21, Núm. 1
2020
-
The interaction between mitochondrial oxidative stress and gut microbiota in the cardiometabolic consequences in diet-induced obese rats
Antioxidants, Vol. 9, Núm. 7, pp. 1-15
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Modification over time of pulse wave velocity parallel to changes in aortic BP, as well as in 24-h ambulatory brachial BP
Journal of Human Hypertension, Vol. 30, Núm. 3, pp. 186-190
2015
-
Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16
-
Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47